drugset / Trial / NCT05781516
Baricitinib Plus Glucocorticoid for Eosinophilia in IgG4-RD
RandomizedParallel-groupOpen-labelTreatment
Summary
Evaluation of efficacy and safety of Baricitinib combined with glucocorticoid in patients of IgG4-related disease with eosinophilia.
Timeline
- Start
- 2023-01-20
- Primary completion
- 2024-06
- Completion
- 2025-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Baricitinib | Small molecule | 2 mg | Oral |
| Background | Prednisolone | Other / unclassified | 0.6 mg/kg | Oral |
| Background | Prednisolone | Other / unclassified | 0.8 mg/kg | Oral |